NO327947B1 - Polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA-sekvenser, fremgangsmater for seleksjon av rekombinante polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, anti-Rhesus D-antistoffer, framgangsmate for fremstilling av fullstendige anti-Rhesus D-antistoffer, farmasoytisk preparat samt diagnostisk preparat for Rhesus D-type bestemmelse - Google Patents
Polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA-sekvenser, fremgangsmater for seleksjon av rekombinante polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, anti-Rhesus D-antistoffer, framgangsmate for fremstilling av fullstendige anti-Rhesus D-antistoffer, farmasoytisk preparat samt diagnostisk preparat for Rhesus D-type bestemmelse Download PDFInfo
- Publication number
- NO327947B1 NO327947B1 NO19986088A NO986088A NO327947B1 NO 327947 B1 NO327947 B1 NO 327947B1 NO 19986088 A NO19986088 A NO 19986088A NO 986088 A NO986088 A NO 986088A NO 327947 B1 NO327947 B1 NO 327947B1
- Authority
- NO
- Norway
- Prior art keywords
- rhesus
- cdr
- antibodies
- antigens
- polypeptides
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 63
- 108091007433 antigens Proteins 0.000 title claims abstract description 63
- 102000036639 antigens Human genes 0.000 title claims abstract description 63
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 38
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims abstract description 18
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims abstract description 18
- 210000003743 erythrocyte Anatomy 0.000 claims description 83
- 238000004091 panning Methods 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 230000009102 absorption Effects 0.000 claims description 18
- 238000010521 absorption reaction Methods 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 230000009257 reactivity Effects 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 101150117115 V gene Proteins 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 230000002949 hemolytic effect Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 102100027544 Blood group Rh(D) polypeptide Human genes 0.000 description 14
- 101000580024 Homo sapiens Blood group Rh(D) polypeptide Proteins 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000004520 agglutination Effects 0.000 description 11
- 238000010276 construction Methods 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000035931 haemagglutination Effects 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000001188 anti-phage Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000000521 hyperimmunizing effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010043461 Deep Vent DNA polymerase Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001446187 Kermes Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CXORMDKZEUMQHX-UHFFFAOYSA-N kermesic acid Chemical compound O=C1C2=C(O)C(O)=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C CXORMDKZEUMQHX-UHFFFAOYSA-N 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96810421 | 1996-06-24 | ||
| PCT/EP1997/003253 WO1997049809A1 (fr) | 1996-06-24 | 1997-06-20 | Olypeptides capables de former des structures de liaison a l'ant igene avec une specificite pour les antigenes de rhesus d, adn les codant et procede pour leur preparation et leur utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO986088D0 NO986088D0 (no) | 1998-12-23 |
| NO986088L NO986088L (no) | 1999-02-24 |
| NO327947B1 true NO327947B1 (no) | 2009-10-26 |
Family
ID=8225636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19986088A NO327947B1 (no) | 1996-06-24 | 1998-12-23 | Polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA-sekvenser, fremgangsmater for seleksjon av rekombinante polypeptider som kan danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, anti-Rhesus D-antistoffer, framgangsmate for fremstilling av fullstendige anti-Rhesus D-antistoffer, farmasoytisk preparat samt diagnostisk preparat for Rhesus D-type bestemmelse |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7038020B1 (fr) |
| EP (1) | EP0920509B1 (fr) |
| JP (1) | JP3841360B2 (fr) |
| KR (1) | KR100361449B1 (fr) |
| AT (1) | ATE272116T1 (fr) |
| AU (1) | AU722127B2 (fr) |
| BG (1) | BG64534B1 (fr) |
| BR (1) | BR9709958A (fr) |
| CA (1) | CA2258494C (fr) |
| CZ (1) | CZ296807B6 (fr) |
| DE (1) | DE69730031T2 (fr) |
| DK (1) | DK0920509T3 (fr) |
| ES (1) | ES2224255T3 (fr) |
| HU (1) | HUP9902605A3 (fr) |
| IL (1) | IL127595A (fr) |
| IS (1) | IS2220B (fr) |
| NO (1) | NO327947B1 (fr) |
| NZ (1) | NZ333329A (fr) |
| PL (1) | PL186019B1 (fr) |
| RU (1) | RU2204602C2 (fr) |
| SK (1) | SK284879B6 (fr) |
| TR (1) | TR199802692T2 (fr) |
| WO (1) | WO1997049809A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1131428A2 (fr) * | 1998-11-19 | 2001-09-12 | Incyte Pharmaceuticals, Inc. | Proteines de la superfamille des immunoglobulines |
| EP1106625A1 (fr) * | 1999-11-17 | 2001-06-13 | ZLB Bioplasma AG | Séquences péptidiques spécifiques pour rhesus D |
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| AU2001253589B2 (en) * | 2000-04-17 | 2007-08-16 | Dyax Corp | Methods of constructing display libraries of genetic packages for members of a diverse family of peptides |
| AU2002226049A1 (en) * | 2000-12-05 | 2002-06-18 | Alexion Pharmaceuticals, Inc. | Engineered plasmids and their use for in situ production of genes |
| US20030119056A1 (en) | 2000-12-18 | 2003-06-26 | Ladner Robert Charles | Focused libraries of genetic packages |
| AU2016225923B2 (en) * | 2001-04-17 | 2018-07-05 | Takeda Pharmaceutical Company Limited | Novel Methods of Constructing Libraries Comprising Displayed and/or Expressed Members of a Diverse Family of Peptides, Polypeptides or Proteins and the Novel Libraries |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| RU2426795C2 (ru) | 2004-07-20 | 2011-08-20 | Симфоген А/С | Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии |
| CA2574062A1 (fr) * | 2004-07-20 | 2006-01-26 | Symphogen A/S | Anticorps polyclonal recombine anti-rhesus d et procedes de production |
| GB0706558D0 (en) * | 2007-04-03 | 2007-05-09 | Common Services Agency For The | Diagnostic assay |
| BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US20090093004A1 (en) | 2007-10-04 | 2009-04-09 | Symphogen A/S | Potency assay |
| US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
| CA2968164C (fr) | 2008-04-24 | 2019-08-20 | Dyax Corp. | Bibliotheques de materiels genetiques comprenant de nouvelles conceptions cdr1, cdr2 et cdr3 hc et de nouvelles conceptions cdr1, cdr2 et cdr3 lc |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| EP2917236A2 (fr) * | 2012-11-06 | 2015-09-16 | MedImmune, LLC | Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv |
| WO2019075523A1 (fr) * | 2017-10-20 | 2019-04-25 | Csl Ltd. | Procédé |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2127434A (en) | 1982-09-17 | 1984-04-11 | Univ London | A human monoclonal antibody against Rhesus D antigen |
| GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
-
1997
- 1997-06-20 AT AT97929244T patent/ATE272116T1/de active
- 1997-06-20 EP EP97929244A patent/EP0920509B1/fr not_active Expired - Lifetime
- 1997-06-20 HU HU9902605A patent/HUP9902605A3/hu unknown
- 1997-06-20 NZ NZ333329A patent/NZ333329A/xx not_active IP Right Cessation
- 1997-06-20 TR TR1998/02692T patent/TR199802692T2/xx unknown
- 1997-06-20 US US09/147,443 patent/US7038020B1/en not_active Expired - Fee Related
- 1997-06-20 PL PL97330794A patent/PL186019B1/pl not_active IP Right Cessation
- 1997-06-20 BR BR9709958A patent/BR9709958A/pt not_active Application Discontinuation
- 1997-06-20 DE DE69730031T patent/DE69730031T2/de not_active Expired - Lifetime
- 1997-06-20 JP JP50232398A patent/JP3841360B2/ja not_active Expired - Lifetime
- 1997-06-20 SK SK1761-98A patent/SK284879B6/sk not_active IP Right Cessation
- 1997-06-20 KR KR10-1998-0710975A patent/KR100361449B1/ko not_active IP Right Cessation
- 1997-06-20 RU RU99101121/13A patent/RU2204602C2/ru not_active IP Right Cessation
- 1997-06-20 WO PCT/EP1997/003253 patent/WO1997049809A1/fr active IP Right Grant
- 1997-06-20 CZ CZ0395998A patent/CZ296807B6/cs not_active IP Right Cessation
- 1997-06-20 IL IL12759597A patent/IL127595A/xx not_active IP Right Cessation
- 1997-06-20 CA CA002258494A patent/CA2258494C/fr not_active Expired - Fee Related
- 1997-06-20 AU AU33423/97A patent/AU722127B2/en not_active Expired
- 1997-06-20 ES ES97929244T patent/ES2224255T3/es not_active Expired - Lifetime
- 1997-06-20 DK DK97929244T patent/DK0920509T3/da active
-
1998
- 1998-12-11 IS IS4922A patent/IS2220B/is unknown
- 1998-12-15 BG BG103016A patent/BG64534B1/bg unknown
- 1998-12-23 NO NO19986088A patent/NO327947B1/no not_active IP Right Cessation
-
2005
- 2005-06-20 US US11/155,775 patent/US7399471B2/en not_active Expired - Fee Related
-
2006
- 2006-01-18 US US11/333,197 patent/US7429647B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7399471B2 (en) | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use | |
| Persson et al. | Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. | |
| JP3653093B2 (ja) | 人化抗体 | |
| US5712120A (en) | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them | |
| CN107973854B (zh) | Pdl1单克隆抗体及其应用 | |
| KR20070038556A (ko) | 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법 | |
| CN108699146A (zh) | 抗pd-l1抗体及其用途 | |
| CN111744013B (zh) | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 | |
| PT1589107E (pt) | Imunoglobulinas desprovidas de cadeias leves | |
| CN101023101A (zh) | 抗－恒河猴d重组多克隆抗体和生产方法 | |
| CN107531797B (zh) | 凝血酶抗体、其抗原结合片段及医药用途 | |
| O’Dwyer et al. | Anti‐ICOSL new antigen receptor domains inhibit T cell proliferation and reduce the development of inflammation in the collagen‐induced mouse model of rheumatoid arthritis | |
| Miescher et al. | Sequence and specificity analysis of recombinant human Fab anti‐Rh D isolated by phage display | |
| Fischer et al. | Platelet‐reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia | |
| CN103588882B (zh) | 针对人cd22抗体的抗独特型抗体及其应用 | |
| US20230086530A1 (en) | Human cd47-targeting single-domain antibody and use thereof | |
| CN114685655B (zh) | Pd-1结合分子及其应用 | |
| Lévy et al. | Molecular characterization of a monoclonal murine anti-blood group A antibody | |
| KR20110047258A (ko) | 저혈소판증의 치료 방법 | |
| WO2024020063A2 (fr) | Anticorps anti-hrf | |
| MXPA99008621A (es) | Peptidos de union a ctla-4, inmunoterapeuticos | |
| Kallewaard | Investigations into the molecular and structural determinants of the human antiviral antibody response to rotavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |